Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Pars Planitis Treatment Market From 2025 to 2029?

There has been robust growth in the treatment market size for pars planitis in recent years. This is projected to increase from $632.88 billion in 2024 to approximately $683.54 billion in 2025, representing a compound annual growth rate (CAGR) of 8.0%. This notable growth observed in the historical period can be linked to heightened awareness of autoimmune eye diseases, a rising number of uveitis cases in children, improved accessibility to eye care, increased usage of immunosuppressants, and enhanced patient understanding of the benefits of early intervention.

In the coming years, the market size for pars planitis treatment is predicted to see robust growth, expanding to a value of $920.48 billion by 2029, with a 7.7% compound annual growth rate (CAGR). This expected growth in the projected timeline can be credited to factors such as the widespread adaptation of biologic therapies, increased incidence of autoimmune ailments, intensified focus on children’s eye care, extended health insurance coverage and heightened demand for bespoke treatment. The forecast period is also likely to witness certain trends like the shift toward steroid-sparing therapies, incorporation of teleophthalmology, the rise of long-acting implants, the application of biosimilars in treatment, and an increase in combination therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24649&type=smp

What Elements Are Contributing To Growth In The Pars Planitis Treatment Market?

The escalating occurrence of pars planitis is anticipated to fuel the expansion of the pars planitis treatment market in the future. Pars planitis is an underspecified type of intermediate uveitis that primarily induces inflammation in the peripheral retina and vitreous, usually affecting individuals between 15 to 40 years. The surging rates of pars planitis are linked to heightened awareness and enhanced diagnostic capabilities, backed by advanced imaging technologies that facilitate early and precise detection. Treatments for pars planitis are instrumental in managing the condition by curbing ocular inflammation, thereby playing a crucial role in preserving vision and warding off complications. They augment patient care by providing specific therapies like corticosteroids and immunosuppressants, thus contributing to improved long-term ocular health and life quality. As per a case study report published by the Mega Journal of Case Reports, a US-based medical publication, in February 2025, intermediate uveitis has an incidence rate of 1.4 to 2 cases per 100,000 individuals, with the idiopathic variety, pars planitis, making up 70% of these cases. Hence, the escalating occurrence of pars planitis propels the expansion of the pars planitis treatment market.

Which Segments Are Detailed In The Global Pars Planitis Treatment Market Report?

The pars planitis treatment market covered in this report is segmented –

1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments

2) By Diagnosis: Blood Tests, X-ray, Magnetic Resonance Imaging (MRI), Other Diagnosis

3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids

2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery

4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy

5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents

6) By Other Treatments: Antibiotics, Antivirals, Laser therapy

Which Emerging Trends And Strategic Shifts Are Shaping The Pars Planitis Treatment Market?

Principal corporations actively participating in the pars planitis treatment market are concentrating on the creation of newfangled solutions, such as bispecific antibodies, aiming to improve immune modulation, decrease ocular inflammation, and cut down on systemic side effects. These bispecific antibodies are customized proteins configured to connect with two dissimilar antigens or targets concurrently, providing more accurate and potent treatment with lesser side effects. For instance, Genentech Inc., a biotechnology firm based in the US, gained Food and Drug Administration approval in October 2023 for Vabysmo (faricimab-svoa), which treats not only retinal vein occlusion (RVO) but also age-related macular degeneration and diabetic macular edema. Vabysmo offers the first bispecific antibody for ophthalmic application targeting both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), managing inflammation and vascular leakage simultaneously. This trailblazing technique is being probed for use in intermediate uveitis, containing pars planitis, wherein long-standing inflammation in the retinal edge demands a sustained and targeted response.

Who Are The Key Contributors To Growth In The Pars Planitis Treatment Market?

Major companies operating in the pars planitis treatment market are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc., Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Quantum Cryogenics Ltd., Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd., Hologic Inc., Aurobindo Pharma Limited, Santen Pharmaceutical Co. Ltd., CooperSurgical Inc., AtriCure Inc., Alimera Sciences Inc., Clearside Biomedical Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pars-planitis-treatment-global-market-report

Which Region Is Projected To Lead The Pars Planitis Treatment Market By 2025?

North America was the largest region in the pars planitis treatment market in 2024. The regions covered in the pars planitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24649&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model